Benitec Biopharma Inc. (BNTC) |
|
0.2316 0.003 (1.31%)
|
06-09 13:33 |
|
Open: |
0.225 |
Pre. Close: |
0.2286 |
|
High:
|
0.239 |
Low:
|
0.220901 |
|
Volume:
|
68,695 |
Market Cap:
|
6(M) |
|
|
|
Technical analysis |
as of: 2023-06-09 1:43:41 PM |
|
Short-term rate:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 0.31 One year: 0.36 |
| Support: |
Support1: 0.18 Support2: 0.15 |
| Resistance: |
Resistance1: 0.26 Resistance2: 0.31 |
| Pivot: |
0.22  |
| Moving Average: |
MA(5): 0.22  MA(20): 0.22
MA(100): 0.23 MA(250): 0.39 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 30.8 %D(3): 29.7 |
| RSI: |
RSI(14): 53 |
| 52-week: |
High: 2.09 Low: 0.13 |
| Average Vol(K): |
3-Month: 308 (K) 10-Days: 255 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ BNTC ] has closed below upper band by 42.0%. Bollinger Bands are 22.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.23 - 0.23 |
0.23 - 0.24 |
|
Low:
|
0.22 - 0.22 |
0.22 - 0.22 |
|
Close:
|
0.23 - 0.23 |
0.23 - 0.23 |
|
Company Description |
|
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California. |
Headline News |
Thu, 18 May 2023
JMP Securities Analyst Reiterates Market Outperform Rating for ... - Best Stocks
Mon, 08 May 2023
Benitec Biopharma to Present at the JMP Securities Life Sciences ... - GlobeNewswire
Mon, 08 May 2023
Benitec Biopharma to Present at the OPMD International Conference - GlobeNewswire
Tue, 21 Feb 2023
7 Cheap Robinhood Stocks Under $1 To Watch Trading For Pennies - Penny Stocks
Mon, 13 Feb 2023
Benitec Biopharma Releases Second Quarter 2023 Financial ... - GlobeNewswire
Mon, 23 Jan 2023
Benitec Biopharma Enrolls First OPMD Subject into the Clinical ... - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
28 (M) |
|
% Held by Insiders
|
2.442e+007 (%) |
|
% Held by Institutions
|
7.9 (%) |
|
Shares Short
|
189 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-1.915e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-28 |
|
Return on Assets (ttm)
|
336.7 |
|
Return on Equity (ttm)
|
-131.8 |
|
Qtrly Rev. Growth
|
68000 |
|
Gross Profit (p.s.)
|
10.86 |
|
Sales Per Share
|
-283.88 |
|
EBITDA (p.s.)
|
55652.2 |
|
Qtrly Earnings Growth
|
-1.4 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-19 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.01 |
|
Price to Cash Flow
|
1.56 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
317360 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
